Wegovy label consolidates four injection formats and tablets into one document
Wegovy's updated US label puts four injection devices and the tablets under one brand name, with a different storage clock and instruction sheet for each.
Novo Nordisk's prescribing information for Wegovy now covers four injection presentations and the oral tablets in a single document, updated June 18, 2026 [2]. Each format carries its own strengths, National Drug Codes and storage window [1][2], so the same brand name and the same molecule — semaglutide — now arrive in packages that behave differently after they are opened.
The injection side alone covers four products: a single-dose pen in five strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg), a 7.2 mg single-dose pen labeled Wegovy HD, a single-dose prefilled syringe in the same five strengths, and the Wegovy FlexTouch multi-dose pen, which holds 9.6 mg/3 mL and delivers four 2.4 mg doses [1][2]. The tablets come in 1.5 mg, 4 mg, 9 mg and 25 mg [1][2].
The label's "Recent Major Changes" list shows how fast the document has moved. Dosage and Administration was revised three times — 08/2025, 12/2025 and 03/2026 — and the June 2026 revision added a warning that FlexTouch must never be shared between patients, even if the needle is changed [1][2]. The two available versions of the label disagree on one date: one marks removal of the Suicidal Behavior and Ideation section as 01/2026 [1], while the DailyMed version shows 02/2026 [2].
Storage is where the consolidation gets practical. Three in-use rules now apply to the same molecule under the same brand name: 28 days for the single-dose devices, 56 days for FlexTouch after first use, and USP controlled room temperature for the tablets [1].
Indications also differ by form. Wegovy injection is indicated with a reduced-calorie diet and increased physical activity to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; to reduce excess weight and maintain weight loss in adults and children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition; and to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (F2 to F3), under accelerated approval [1]. The tablets carry the cardiovascular and weight indications for adults only — not MASH, and not pediatric patients [2]. Usual maintenance dosing is 2.4 mg once weekly by injection [1][2] or 25 mg once daily as a tablet for cardiovascular risk reduction and weight reduction in adults [2].
Other parts of the label are unchanged in substance. The boxed warning about thyroid C-cell tumors in rodents, and the contraindication for patients with a personal or family history of medullary thyroid carcinoma or MEN 2, remain [1]. Combining Wegovy with another semaglutide-containing product or any other GLP-1 receptor agonist is still not recommended [1][2].
Why it matters for patients
A Wegovy prescription no longer identifies a single set of handling rules. A single-dose pen and a FlexTouch pen are the same drug from the same company, but an opened single-dose device has a 28-day window and FlexTouch has 56 days, and only FlexTouch carries the do-not-share warning [1]. The device dispensed at the pharmacy determines which Instructions for Use apply and how long the product can be used after first use [1][2].
The tablets are not a drop-in substitute for the injection. Their approved uses are narrower — adults, cardiovascular risk reduction and weight reduction, with no MASH and no pediatric indication — and they must be taken once daily on an empty stomach in the morning with no more than 4 ounces of water, swallowed whole, followed by at least 30 minutes before food, other drinks or other oral medicines [1][2]. The label does include a section on switching between the injection and the tablets [1].
What happens next
The label is current as of June 18, 2026 [2]. The MASH indication was granted under accelerated approval, and continued approval for that use may depend on a confirmatory trial [1]. Whether Novo Nordisk plans additional presentations, or further consolidation of the label, has not been disclosed.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.